Core Insights - Profusa, Inc. is set to present findings from its pilot clinical study on Lumee technology for tissue oxygen monitoring in peripheral artery disease (PAD) patients at the Leipzig Interventional Course (LINC) 2026 [1][2] - The Lumee technology allows for continuous, real-time measurement of tissue oxygen, intended for both clinical and home use, with positive feedback received from the U.S.-based clinical study [2][3] - Profusa aims to provide personalized biochemical signatures through its long-lasting, injectable biosensors and intelligent data platform, enhancing the reliability of medical data for clinicians [3] Company Overview - Profusa is a commercial stage digital health company based in Berkeley, California, focusing on the development of tissue-integrated sensors that transmit actionable medical-grade data [3] - The company is led by experienced scientific founders and management, supported by a world-class board of directors [3] - Profusa's mission is to create affordable biosensors that provide continuous monitoring of biochemistry, thereby improving patient care and outcomes [3]